Preferred Networks and Listing Agreements: How Are They Measuring Up? The Impact on Patients Outcomes and Value for Plan Sponsors
B.Sc. Phm., R.Ph.
Director, The Pangaea Group
B.Sc. Phm., R.Ph.
Director, Pharmaceutical Benefits
Sun Life Financial
Roubaix Strategies Inc.
Our theme this season is Making the Link: Financial Sustainability and Measuring Outcomes. In our last session representatives from the Drug Programs Branch of the Ontario Ministry of Health and Long-Term Care, and the Canadian Life and Health Insurance Association explored the integration of private and public drug plans for reimbursement purposes.
If you are an advisor and any of your clients have a biologic, biosimilar or specialty drug on their experience report you should attend this session.
With the increased prevalence of preferred networks and listing agreements in the private drug plan space, it is important for stakeholders to be able to effectively assess the impact of these approaches on health outcomes and economic value for plan members and plan sponsors. Moreover, it is becoming more challenging to differentiate between the various providers’ programs. At our this session we will help unravel the mystery behind the impact on plan members and plan sponsors of these networks and agreements.
Registration, breakfast and networking: 7:30 – 8:00am
Presentations and Panel Discussion: 8:00 – 10:30am
Bev Herczegh will discuss how other countries are addressing the entry of biosimilars, and Health Canada’s guidelines on interchangeability between original biologics and biosimilars. She will also provide insights into how various provinces and the private sector are managing interchangeability, and will comment on the role and impact of efficacy and price in determining which drug a patient receives.
Atul Goela will address preferred provider networks (PPNs) and product listing agreements (PLAs). He will speak from his own perspective as a pharmacist as well as that of his role with Sun Life. Mr. Goela will also comment on how PPNs and PLAs may evolve in the future.
John-Paul Dowson will speak to PLAs and the private payer market, how these agreements are being constructed, their impact, and how to assure quality and value. He will also reflect on the comments from our first two presenters.
Please also join us for the interactive panel discussion that will follow.